An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia

BJU International

Volumn 97, Issue 5, 2006, Pages 1007-1016

  Disantostefano, Rachael L ^a   Biddle, Andrea K ^a   Lavelle, John P ^b  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Benign prostatic hyperplasia; Economic; Outcome assessment

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CATHETERIZATION; CAUSE OF DEATH; CLINICAL FEATURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; ERECTILE DYSFUNCTION; EVALUATION; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; INCONTINENCE; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; PATIENT CARE; PRIORITY JOURNAL; PROBABILITY; PROSTATE HYPERTROPHY; SOCIETY; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL RESECTION; TREATMENT FAILURE; TREATMENT OUTCOME; URETHRA DISEASE; URINARY TRACT DISEASE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; HOSPITALIZATION; HUMANS; HYPERTHERMIA, INDUCED; MALE; MARKOV CHAINS; MIDDLE AGED; PROSTATIC HYPERPLASIA; TESTOSTERONE 5-ALPHA-REDUCTASE; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME;

EID: 33645728233     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.06089.x     Document Type: Article

References (54)

1. McConnell JD. The pathophysiology of benign prostatic hyperplasia. J Androl 1991 12 356 63
2. Chute CG Panser LA Girman CJ et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993 150 85 9
3. Jepsen JV Bruskewitz RC. Comprehensive patient evaluation for benign prostatic hyperplasia. Urology 1998 51 Suppl. 4A 13 8
4. Foley CL Taylor C Kirby RS. Counting the cost of treatment benign prostatic hyperplasia. BJU Int 2004 93 250 2
5. Jepsen JV Bruskewitz RC. Recent developments in the surgical management of benign prostatic hyperplasia. Urology 1998 51 Suppl. 4A 23 31
6. Mundy AR. The future of urology. BJU Int 2003 92 337 9
7. Singh R O'Brien TS. The relationship between volume and outcome in urological surgery. BJU Int 2004 93 931 5
8. Chirikos TN Sanford E. Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. J Urol 1996 155 1311 6
9. Lowe FC McDaniel RL Chmiel JJ Hillman AL. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology 1995 46 477 83
10. Albertsen PC Pellissier JM Lowe FC Girman CJ Roehrborn CG. Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study. Clin Ther 1999 21 1006 24
11. Barry MJ Mulley AG Fowler FJ Wennberg JW. Watchful waiting vs immediate transurethral resection for symptomatic prostatism. The importance of patients' preferences. JAMA 1988 259 3010 7
12. Bisonni RS Lawler FH Holtgrave DR. Transurethral prostatectomy versus transurethral dilatation of the prostatic urethra for benign prostatic hyperplasia: a cost-utility analysis. Fam Pract Res J 1993 13 25 36
13. Baladi JF Menon D Otten N. An economic evaluation of finasteride for treatment of benign prostatic hyperplasia. Pharmacoeconomics 1996 9 443 54
14. Blute M Ackerman SJ Rein AL et al. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part II - results. Urology 2000 56 981 7
15. Noble SM Coast J Brookes S et al. Transurethral prostate resection, noncontact laser therapy or conservative management in men with symptoms of benign prostatic enlargement? An economic evaluation. J Urol 2002 168 2476 82
16. McDonald H Hux M Brisson M Bernard L Nickel JC. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. Can J Urol 2004 11 2327 40
17. Cockrum PC Finder SF Ries AJ Potyk RP. A pharmacoeconomic analysis of patients with symptoms of benign prostatic hyperplasia. Pharmacoeconomics 1997 11 550 65
18. Norby B Nielsen HV Frimodt-Moller PC. Transurethral interstitial laser coagulation of the prostate and transurethral microwave thermotherapy vs transurethral resection or incision of the prostate: results of a randomized, controlled study in patients with symptomatic benign prostatic hyperplasia. BJU Int 2002 90 853 62
19. Walden M Acosta S Carlsson P Pettersson S Dahlstrand C. A cost-effectiveness analysis of transurethral resection of the prostate and transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia: two-year follow-up. Scand J Urol Nephrol 1998 32 204 10
20. Roehrborn CG McConnell JD Barry MJ et al. AUA guideline on the management of benign prostatic hyperplasia 2003. Available from: http://www.auanet.org/ guidelines/bph.cfm. Accessed December 2005
21. de La Rosette JJ Floratos DL Severens JL Kiemeney LA Debruyne FM Pilar Laguna M. Transurethral resection vs microwave thermotherapy of the prostate: a cost-consequences analysis. BJU Int 2003 92 713 8
22. McConnell JD Roehrborn CG Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 349 2387 98
23. Wasson JH Reda DJ Bruskewitz RC Elinson J Keller AM Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995 332 75 9
24. Wickware P. BPH: Conservative treatment equals extravagant costs. Urol Times 2000 28 22
25. Sox HC Blatt MA Higgins MC Marton KI. Medical Decision Making. Boston Butterworth Heinemann 1988
26. Briggs A Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998 13 397 409
27. DiSantostefano RL Biddle AK Lavelle JP. The long-term cost-effectiveness of treatments for benign prostatic hyperplasia. Pharmacoeconomics 2006 24 171 91
28. McConnell JD Barry MJ Bruskewitz RC. Benign prostatic hyperplasia. diagnosis and treatment. Clinical Practice Guideline, number 8, AHCPR Publication no. 94-0582. Rockville, MD Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services February 1994
29. Verhamme KM Dieleman JP Bleumink GS Bosch JL Stricker BH Sturkenboom MC. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol 2003 44 539 45
30. Lipscomb J Weinstein MC et al. Time Preference. In Gold MR Siegel JE Russell LB Weinstein MC Cost-Effectiveness in Health and Medicine. New York Oxford University Press 1996
31. Merck Inc. Proscar package insert. Available from: http://www.proscar. com/proscar/shared/documents/pi.pdf Accessed December 2005
32. Larson TR Blute ML Bruskewitz RC Mayer RD Ugarte RR Utz WJ. A high-efficiency microwave thermoablation system for the treatment of benign prostatic hyperplasia: results of a randomized, sham-controlled, prospective, double-blind, multicenter clinical trial. Urology 1998 51 731 42
33. Floratos DL Kiemeney LA Rossi C Kortmann BB Debruyne FM de La Rosette JJ. Long-term followup of randomized transurethral microwave thermotherapy versus transurethral prostatic resection study. J Urol 2001 165 1533 8
34. Briggs AH Ades AE Price MJ. Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Med Decis Making 2003 23 341 50
35. Miniño AM Arias E Kochanek KD Murphy SL Smith BL. Deaths: final data for 2000. National vital statistics reports 2002 50 15 1 120. Hyattsville, MD National Center for Health Statistics. Available from: http://www.cdc.gov/ nchs/data/nvsr/nvsr50/nvsr50_15.pdf Accessed December 2005
36. Flanigan RC Reda DJ Wasson JH Anderson RJ Abdellatif M Bruskewitz RC. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998 160 12 7
37. Agency for Healthcare Research and Quality. Healthcare cost and utilization project (HCUP) national inpatient sample [database on CD ROM or online]. Available from: http://www.ahrq.gov/data/hcup/. Accessed December 2005
38. Madsen P Iversen P. A point system for selecting operative candidates. In Benign Prostatic Hypertrophy. New York Springer-Verlag 1983 763 5
39. IHCIS. IHCIS national managed care benchmark database. [database on tape]. Available from: http://www.ihcis.com/information_services/. Accessed December 2005
40. TM for Windows®. [electronic database]. Available from: http://scientific.thomson.com/support/products/ redbook/. Accessed December 2005
41. Centers for Medicine and Medical Services (CMS), HHS. Medicare program; changes to the hospital inpatient prospective payment systems and fiscal year 2004 rates. Final rule. Fed Regist 2003 68 45345 672
42. Centers for Medicine and Medical Services (CMS), HHS. Medicare program; revisions to payment policies under the physician fee schedule for calendar year 2004. Final rule with comment period. Fed Regist 2003 68 63195 395
43. Rossi C Kortmann BB Sonke GS et al. alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. J Urol 2001 165 38 41
44. Sandhu JS Te AE. The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data. Curr Urol Rep 2004 5 274 9
45. Turner K McNeill SA. MTOPS: conclusions about invasive therapy for BPH should be interpreted with caution. BJU Int 2004 94 1143
46. Madersbacher S Marberger M. Is transurethral resection of the prostate still justified? BJU Int 1999 83 227 37
47. de la Rosette JJ Laguna MP Gravas S de Wildt MJ. Transurethral microwave thermotherapy: the gold standard for minimally invasive therapies for patients with benign prostatic hyperplasia? J Endourol 2003 17 245 51
48. D'Ancona FC Francisca EA Witjes WP Welling L Debruyne FM De La Rosette JJ. Transurethral resection of the prostate vs high-energy thermotherapy of the prostate in patients with benign prostatic hyperplasia: long-term results. Br J Urol 1998 81 259 64
49. Thomas AW Cannon A Bartlett E Ellis-Jones J Abrams P. The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic followup. BJU Int 2004 93 745 50
50. Maria G Brisinda G Civello IM Bentivoglio AR Sganga G Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003 62 259 65
51. Plante MK Folsom JB Zvara P. Prostatic tissue ablation by injection: a literature review. J Urol 2004 172 20 6
52. Llewellyn-Thomas HA Williams JI Levy L Naylor CD. Using a trade-off technique to assess patients' treatment preferences for benign prostatic hyperplasia. Med Decis Making 1996 16 262 82
53. Ackerman SJ Rein AL Blute M et al. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods. Urology 2000 56 972 80
54. Cher DJ Miyamoto J Lenert LA. Incorporating risk attitude into Markov-process decision models: importance for individual decision making. Med Decis Making 1997 17 340 50